by The Global Antibody Drug Conjugates Market is estimated to be valued at US$ 5.38 Bn or Mn in 2023 and is expected to exhibit a CAGR of 14.2% over the forecast period 2023-2030, as highlighted in a new report published by Coherent Market Insights.
Market Overview:
Antibody drug conjugates (ADCs) are a type of drugs used to treat cancer by simultaneously delivering chemotherapy drugs to tumor cells. ADCs link monoclonal antibodies to powerful cell-killing agents using chemical linkers. This targets delivery of the cytotoxic drug to the cancer cell, reducing systemic exposure and side effects of treatment. With advancement in linker technology, ADCs have demonstrated improved efficacy and safety over traditional chemotherapy drugs.
Market key trends:
One of the key trends in the antibody drug conjugates market is the development of next generation linkers and payloads. Drug development companies are focusing on linker and payload technologies that improve stability, safety and tolerability of ADCs. For instance, ProfoundBio is developing PYC therapy with their stabilized linker-drug conjugate platform. Companies are also exploring new payloads like camptothecin analogs and pyrrolobenzodiazepines which show promise of delivering higher potency ADCs. Another key trend is the increasing clinical pipeline of ADCs. As of 2021, over 100 ADCs were in clinical trials across various cancer indications. With ongoing R&D and advancement in linker technologies, the clinical success and adoption of ADCs is expected to significantly grow over the forecast period.
Porter’s Analysis
Threat of new entrants: The biopharmaceutical industry requires high capital investments and strict regulatory approvals which pose significant barriers for new entrants in the ADC market.
Bargaining power of buyers: The presence of several large pharmaceutical players as buyers limits their bargaining power. However, higher treatment costs give them some bargaining leverage.
Bargaining power of suppliers: Major technology players controlling crucial antibody-drug technologies exert strong influence on market players and terms.
Threat of new substitutes: Novel drug modalities like monoclonal antibodies, bispecific antibodies and cellular therapies pose competition but lack complete substitutability.
Competitive rivalry: Intense competition exists among major players to gain FDA approvals and market share. Large R&D investments and collaborations have increased competitive pressures in the market.
Key Takeaways
The Global Antibody Drug Conjugates Market is expected to witness high growth, exhibiting a CAGR of 14.2% over the forecast period, due to increasing approvals and launches of novel ADCs.
Regionally, North America is expected to dominate the ADC market through 2030 owing to presence of major players and huge biopharmaceutical R&D investments. However, Asia Pacific is anticipated to be the fastest growing regional market due to growing immunotherapy adoption and increasing generic competition.
Key players operating in the Antibody Drug Conjugates market are AstraZeneca PLC, Daiichi Sankyo Company, Limited, Novasep, ADC Therapeutics SA, Alentis Therapeutics AG, F. Hoffmann-La Roche, Gilead Sciences, Inc., AbbVie Inc., Biosion USA, Inc., Astellas Pharma Inc., Duality Biologics (Suzhou) Co. Ltd., BioNTech SE, LaNova Medicines Ltd., Bliss Biopharmaceutical, Eisai Co., Ltd., ProfoundBio, Pfizer, Inc., ImmunoGen Inc., Mersana Therapeutics Inc., Sorrento Therapeutics Inc., Oxford BioTherapeutics Ltd, and Takeda Pharmaceutical Company Ltd. Major players are focused on developing novel ADCs for various cancer types through clinical trials and collaborations.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
